BLU-263 for indolent mast cell disease with symptom control
Part of Cancer, Immune system & allergy clinical trials.
This trial tests BLU-263, a study medicine, against placebo (inactive treatment) to see if it improves symptoms in people with indolent systemic mastocytosis. It also checks safety and how well the dose is tolerated before and during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with indolent systemic mastocytosis (ISM), confirmed by a specialist central lab review.
- Your mast disease symptoms are not controlled enough despite trying at least two standard symptom treatments.
- Your symptom-control treatments have been stable for at least 14 days before screening.
- If you use steroids, your dose is no more than 20 mg/day prednisone (or equivalent) and has been stable for at least 14 days.
- Your general health/function is good enough (ECOG score 0 to 2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is observing adults with indolent systemic mastocytosis (ISM) who are already receiving or planning to start symptom treatments or the drug avapritinib. It aims to learn more about how these treatments work in real life.
This study looks at how avapritinib works in people with indolent systemic mastocytosis whose symptoms are not well controlled by other treatments. You will take the drug as part of your usual care, and researchers will collect information to see how well it helps.
This Phase 2 study tests bezuclastinib, a targeted medicine, in people with advanced systemic mastocytosis (including certain advanced forms with blood cancers). It aims to shrink measurable disease and improve symptoms, while helping people who may also need treatment for an associated blood cancer.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
This Phase 2 study tests iberdomide alone or with low-dose dexamethasone in people with intermediate- or high-risk “smoldering” multiple myeloma. The goal is to see if the treatment can control or delay progression to active myeloma.
This trial tests a new drug, BMS-986453, for people newly diagnosed with multiple myeloma. It aims to see if the drug is safe and works well for those who cannot or choose not to have a stem cell transplant.
Hear when a new Indolent Systemic Mastocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.